Abstract
Olopatadine hydrochloride (Olopatadine) is an antiallergic drug with selective histamine H1 receptor antagonist activity. This study was undertaken to clarify the effects of Olopatadine on CCL17 and CCL22 production by PBMCs from patients with AD during the treatment. We measured the levels of CCL17, CCL22, IFNγ, IL-12 and IL-18 in plasma and the supernatants of cultured PBMCs with or without dust mite allergen extract (DME) in the AD patients before and after treatment with oral Olopatadine (10mg/day) for 4 weeks. The plasma levels of CCL17 and CCL22 significantly decreased after the treatment compared with before the treatment and were significantly correlated with SCORAD index. PBMCs from AD patients taken after the treatment and cultured with DME for 5 days, showed significantly lower levels of CCL17 production than those taken before the treatment and cultured with DME for 5 days. Our data demonstrate that Olopatadine inhibits CCL17 and CCL22 production by PBMCs from AD patients, which are important regulators of Th2 recruitment in the skin.
